drugset / Trial / NCT00078637

Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma

NCT00078637

Phase 1 Completed 37 enrolled Eisai Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a first-in-man, open-label, non-randomized, multiple dose, multiple cycle, dose escalation study to determine the MTD, safety, PK, and pharmacodynamics of E7820 in patients with a malignant solid tumor or lymphoma.

Timeline

Start
2004-01
Primary completion
2006-08
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject E7820 Small molecule Oral

Indications